2023-06-26 09:38:25 ET
- The European Commission has awarded orphan drug status to ALX Oncology's ( NASDAQ: ALXO ) evorpacept for gastric cancer.
- The classification covers both gastric cancer and gastroesophageal junction adenocarcinoma.
- The US FDA granted orphan drug status for the candidate for the gastric cancer indication in January 2022.
- ALX ( ALXO ) plans to release data in H2 of this year from ASPEN-06, a phase 2 trial of evorpacept in combination with trastuzumab, paclitaxel and Eli Lilly ( LLY ) Cyramza (ramucirumab) for the HER2-positive gastric cancer.
- Seeking Alpha's Quant Rating views ALX Oncology ( ALXO ) as a hold.
For further details see:
ALX Oncology gastric cancer candidate wins orphan drug status from EC